Clinical Trial Search

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 2; 19; 26; 6 Participants

Primary: Percentage of Participants in Arms A and B With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.1; 100 percentage of participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm — 1.1; 0.4 percentage of…

Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…

Primary: 15-Item Word List Delayed Recall — -0.3; -0.5 units on a scale - change from baseline — p=<.05

Primary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 92.4; 93.0 percentage of participants…

Primary: Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I — -3.46; -6.58; -5.65 units on a scale — p=<0.001

Primary: TD1414 Serum Concentration by Timepoint — 624.3; 864.1; 1195.7; 888.4 pg/mL

Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001

Primary: Patient Rating of Shared Decision Making — 66.7; 72.0; 74.7; 74.7 percentage of participants

Primary: Change in Relative Abundance of Lactobacillus Species — .0084; -.0014; -.00004; .0104 relative abundance

Primary: Nasal Obstruction/Congestion Score — 3.62; 3.30; 2.31; 2.62 units on a scale — p=0.1365

Primary: Mean Intraocular Pressure (IOP) — 9.4; 9.5; 10.0 mmHG

Primary: Primary Hernia Recurrence Rate at 24 Month Follow-up. — 3 Participants